Evidence map›Paper›PMID 36905968›Full record

ArticleBioorganic & medicinal chemistry letters2023

20S proteasome hydrolysis of LLVY substrates to determine preferences for moieties in its primed substrate channel.

Christine S Muli, Darci J Trader

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Christine S MuliDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, United States.
Darci J TraderDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, United States. Electronic address: dtrader@purdue.edu.
Purdue University West Lafayette · US

Funding

Monitoring and Manipulating the Activity of the Immunoproteasome with Small MoleculesR01AI150847 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI TRADER, DARCI J · 2020 to 2023
$1.9M
Development of Activity-Based Chemical Reporters to Differentiate Proteasome Isoforms in CellsR21GM131206 · NIGMS · PURDUE UNIVERSITY · PI TRADER, DARCI J · 2019 to 2020
$426k
Investigating the Interaction of a Selective Peptoid Probe and Rpn-13, A Non-Essential Ubiquitin Receptor of the ProteasomeF31CA247327 · NCI · PURDUE UNIVERSITY · PI MULI, CHRISTINE S · 2020 to 2022
$124k
NCI NIH HHS F31 CA247327NIAID NIH HHS R01 AI150847NIGMS NIH HHS R21 GM131206
6 · The paper itself

Abstract

The proteasome is an essential multi-catalytic enzyme in cells that is responsible for degrading proteins with a ubiquitin-dependent or -independent mechanism. Many activity-based probes, inhibitors, and stimulators have been developed to study or modulate the activity of the proteasome. The development of these proteasome probes or inhibitors have been based on their interaction with the amino acids of the β5 substrate channel proceeding the catalytically active threonine residue. There is potential for positive interactions with a substrate to increase selectivity or cleavage rate with the β5 substrate channel after the catalytic threonine as evidenced by the proteasome inhibitor belactosin. To study what moieties the proteasome could accept in its primed substrate channel, we developed a liquid chromatography- mass spectrometry (LC-MS) method to quantitate the cleavage of substrates by purified human proteasome. This method allowed us to rapidly evaluate proteasome substrates that contain a moiety that could interact with the S1' site of the β5 proteasome channel. We were able to determine a preference for a polar moiety at the S1' substrate position. We believe this information can be used in the design of future inhibitors or activity-based probes for the proteasome.

Indexed as

Proteasome Endopeptidase ComplexProteasome InhibitorsHumansHydrolysisSubstrate SpecificityThreonineProteasome Endopeptidase ComplexProteasome InhibitorsThreonineMass spectrometryPrimed substrate channelProteasome

Identifiers

PMID36905968
PMCPMC10165662
OpenAlexW4323669882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.